News
Health Canada approves Reblozyl to treat transfusion-dependent anemia resulting from low/intermediate risk myelodysplastic syndromes. - BMS.
-Bristol Myers Squibb Canada and Acceleron Pharma Inc. announced that Health Canada has approved Reblozyl (luspatercept for injection) for the treatment of adult patients with transfusion-dependent anemia requiring at least two RBC red blood cell (RBC) units over 8 weeks resulting from very low-to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.
Reblozyl represents a new class of treatment for eligible patients as the first and only approved erythroid maturation agent in Canada.
Condition: Myelodysplastic Syndromes
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins